VAXNEUVANCE, suspension injectable en seringue préremplie.Vaccin pneumococcique polyosidique conjugué (15-valent, adsorbé)

suspension injectable · intramusculaire

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formsuspension injectable

Routeintramusculaire

Ingredient entries15

CountryFrance

Product identity

At a glance

Authorisation holder: MERCK SHARP & DOHME (PAYS-BAS)
Authorisation status: Autorisation active
Market status: Commercialisée
Country: France
Source reference: CIS 64355843

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for VAXNEUVANCE, suspension injectable en seringue préremplie.Vaccin pneumococcique polyosidique conjugué (15-valent, adsorbé)
Ingredient	Strength / reference	Source role
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 19F CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 12
POLYOSIDE PNEUMOCOCCIQUE DE SÉROTYPE 22F CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 13
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 3 CONJUGUÉ À LA PROTÉINE VECTRICE CRM 197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 2
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 6A CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 5
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 14 CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 9
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 9V CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 8
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 4 CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 3
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 1 CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 1
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 6B CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	4,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 6
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 19A CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 11
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 23F CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 14
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 7F CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 7
POLYOSIDE PNEUMOCOCCIQUE DE SÉROTYPE 33F CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 15
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 18C CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 10
POLYOSIDE PNEUMOCOCCIQUE SÉROTYPE 5 CONJUGUÉ À LA PROTÉINE VECTRICE CRM197suspension	2,0 microgrammes de polyoside pneumococciqueune dose de 0,5 mL	SAGroup 4

Pack references

Presentations (1)

1 seringue préremplie en verre de 0,5 ml + 1 aiguille séparée

CIP13 3400930244371

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 64355843 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source file	Retrieved	Source file modified
fr_products.txt	2026-09-17	Not supplied
fr_composition.txt	2026-09-17	Not supplied
fr_packs.txt	2026-09-17	Not supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →